-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex Announces First Patient Enrolled In Acclaim-3 Phase 2 Study For ES-SCLC; 25 Patients To Complete Enrollment In H2 2025; Study Has FDA Orphan Drug And Fast Track Designations

Benzinga·01/23/2025 13:01:10
Listen to the news

Expects to Complete Enrollment of First 25 Patients in Phase 2 Expansion Study During Second Half of 2025 for Interim Analysis

Acclaim-3 Study Has FDA Orphan Drug and Fast Track Designations

AUSTIN, Texas, Jan. 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company's Acclaim-3 clinical study of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC).